Morgan Stanley maintained a Buy rating on Haleon plc, noting its growth in EMEA/LatAm and Asia-Pacific, while reporting a decline in North America, amidst the backdrop of Trump-era tariffs benefiting AI stocks.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley maintained a Buy rating on Haleon plc, noting its growth in EMEA/LatAm and Asia-Pacific, while reporting a decline in North America, amidst the backdrop of Trump-era tariffs benefiting AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Haleon
British multinational consumer healthcare company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
Coverage
Newest first; wire copies grouped- Insider MonkeyMorgan Stanley Maintains a Buy on Haleon plc (HLN) With a PT of $10.95 Haleon plc (NYSE:HLN) is one of the best NYSE stocks to buy under $20. In a report released on August 4, Morgan Stanley maintain